title: GMC is criticised for refusing to disclose reasons behind its advice to support prescribing for Lucentis rather than Avastin for wet AMD.
authors: The BMJ.
authors: Deborah
authors: D
authors: Cohen
mesh_terms: D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage*; D000068258:Bevacizumab; D004992:Ethics, Medical; D006801:Humans; D008268:Macular Degeneration / Q000188:drug therapy*; D056687:Off-Label Use / Q000941:ethics* / Q000331:legislation & jurisprudence; D010818:Practice Patterns, Physicians' / Q000941:ethics / Q000592:standards / Q000706:statistics & numerical data / Q000639:trends; D000069579:Ranibizumab; D016896:Treatment Outcome; D014342:Truth Disclosure / Q000941:ethics; D006113:United Kingdom
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D000069579:Ranibizumab